Back to List

Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation

Minsun Jung et al. — ASCO(2022)

Abstract



Background:

Human epidermal growth factor receptor 2 (HER2) expression is a predictive marker for HER2-targeted therapy in breast cancer patients. Interobserver variation in the interpretation of HER2 levels exists among pathologists, thus a method to increase the consistency of evaluation is needed. This study aimed to evaluate the performance of the artificial intelligence (AI)-based Lunit SCOPE HER2 in assisting pathologists to evaluate HER2 expression levels in breast cancer.



Methods:

Lunit SCOPE HER2 was developed with a 1.04 x 1010 μm2 area and 7.31 x 105 tumor cells from 1,133 HER2 immunohistochemistry stained whole-slide images (WSI) of breast cancer, annotated by 113 board-certified pathologists. The AI model was developed based on a semantic segmentation algorithm, which consists of two atrous spatial pyramid pooling blocks for tissue level classification and for tumor cell level classification. To validate the model, a total of 209 HER2 WSIs diagnosed with breast cancer were obtained from Kyung Hee University Hospital in Korea and were assigned as an external validation set. Three board-certified pathologists evaluated slide level HER2 expression (3+, 2+, 1+, and 0) twice, first without AI assistance and second, with it. The second reading was performed for WSIs where the pathologist's reading showed discrepancy with the AI model.



Results:

In the external validation set, all pathologists scored the same HER2 grade in 103 WSIs (49.3%), and the Fleiss kappa value was 0.512. The HER2 grade from the AI model and pathologists was the same in 151 WSIs (72.2%), and the weighted kappa value was 0.844. The pathologists re-evaluate 43, 63, and 83 WSIs, respectively. After AI assistance, all pathologists scored the same HER2 grade in 156 WSIs (74.6%), and the Fleiss kappa value increased to 0.762 (Table 1).



Conclusions:

This study demonstrates that an AI-powered HER2 analyzer can help achieve consistent HER2 expression level evaluation in breast cancer by reducing interobserver variability. Thus, the AI model can be applied as an assistance tool for pathologists in HER2 grade evaluation.


Table 1. Changes in concordance of pathologists’ HER2 evaluation after AI assistance







Read the full paper
AUTHORS

Minsun Jung1, Seung Geun Song2, Soo Ick Cho3, Wonkyung Jung3, Chiyoon Oum3, Heon Song3, Minuk Ma3, Seonwook Park3, Sergio Pereira3, Sanghoon Song3, Kyunghyun Paeng3, Donggeun Yoo3, Chan-Young Ock3, Ji-Youn Sung4, So-Woon Kim4

1Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. 2Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. 3Lunit Inc., Seoul, Republic of Korea. 4Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea.

PUBLISHED
ASCO(2022)

Read more